Analysts Offer Insights on Healthcare Companies: Nivalis Therapeutics (NASDAQ: NVLS) and Recro Pharma (NASDAQ: REPH)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nivalis Therapeutics (NASDAQ: NVLS) and Recro Pharma (NASDAQ: REPH) with bullish sentiments.

Nivalis Therapeutics (NASDAQ: NVLS)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Nivalis Therapeutics (NASDAQ: NVLS) today and set a price target of $6. The company’s shares opened today at $2.87, close to its 52-week low of $2.58.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.9% and a 46.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies S.A. – American, and Proteostasis Therapeutics Inc.

Nivalis Therapeutics has an analyst consensus of Hold, with a price target consensus of $6.

Recro Pharma (NASDAQ: REPH)

H.C. Wainwright analyst Ed Arce reiterated a Buy rating on Recro Pharma (NASDAQ: REPH) today. The company’s shares opened today at $9.48.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 4.8% and a 37.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics, Inc., and Sucampo Pharmaceuticals.

Recro Pharma has an analyst consensus of Strong Buy.